Dewangan Jayant, Srivastava Sonal, Mishra Sakshi, Pandey Prabhash Kumar, Divakar Aman, Rath Srikanta Kumar
Genotoxicity Lab, Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India.
Biochem Biophys Res Commun. 2018 Jan 8;495(2):1915-1921. doi: 10.1016/j.bbrc.2017.11.199. Epub 2017 Dec 5.
Human triple-negative breast cancer (TNBC) is poorly diagnosed and unresponsive to conventional hormone therapy. Chetomin (CHET), a fungal metabolite synthesized by Chaetomium cochliodes, has been reported as a promising anticancer and antiangiogenic agent but the complete molecular mechanism of its anticancer potential remains to be elucidated. In our study, we explored the anti-neoplastic action of CHET on TNBC cells. Cytotoxicity studies were performed in human TNBC cells viz. MDA-MB-231 and MDA-MB-468 cells by Sulforhodamine B assay. It exhibited antiproliferative response and induced apoptosis in both the cell types. Cell cycle analysis revealed that it increases the sub G0/G1 phase cell population. Modulation of mitochondrial membrane potential, activation of caspase 3/7 and a remarkable increase in the expression of cleaved PARP and increased chromatin condensation was observed after CHET treatment in MDA-MB-231 and MDA-MB-468 cells. Additionally, an elevated level of intracellular Ca played an important role in CHET mediated cell death response. Calcium overload in mitochondria led to release of cytochrome c which in turn triggered caspase-3 mediated cell death. Inhibition of calcium signalling using BAPTA-AM reduced apoptosis confirming the involvement of calcium signalling in CHET induced cell death. Chetomin also inhibited PI3K/mTOR cell survival pathway in human TNBC cells. The overall findings suggest that Chetomin inhibited the growth of human TNBC cells by caspase-dependent apoptosis and modulation of PI3K/mTOR signalling and could be used as a novel chemotherapeutic agent for the treatment of human TNBC in future.
人类三阴性乳腺癌(TNBC)诊断困难,对传统激素疗法无反应。chetomin(CHET)是由卷枝毛壳菌合成的一种真菌代谢产物,已被报道为一种有前景的抗癌和抗血管生成剂,但其抗癌潜力的完整分子机制仍有待阐明。在我们的研究中,我们探讨了CHET对TNBC细胞的抗肿瘤作用。通过磺酰罗丹明B测定法在人TNBC细胞即MDA-MB-231和MDA-MB-468细胞中进行细胞毒性研究。它在两种细胞类型中均表现出抗增殖反应并诱导凋亡。细胞周期分析表明它增加了亚G0/G1期细胞群体。在MDA-MB-231和MDA-MB-468细胞中用CHET处理后,观察到线粒体膜电位的调节、半胱天冬酶3/7的激活以及裂解的PARP表达的显著增加和染色质浓缩增加。此外,细胞内Ca水平升高在CHET介导的细胞死亡反应中起重要作用。线粒体中的钙超载导致细胞色素c释放,进而触发半胱天冬酶-3介导的细胞死亡。使用BAPTA-AM抑制钙信号传导减少了细胞凋亡,证实了钙信号传导参与CHET诱导的细胞死亡。Chetomin还抑制人TNBC细胞中的PI3K/mTOR细胞存活途径。总体研究结果表明,Chetomin通过半胱天冬酶依赖性凋亡和PI3K/mTOR信号传导的调节抑制人TNBC细胞的生长,未来可作为治疗人TNBC的新型化疗药物。